Replimune Group (REPL) pipeline and stated timing

Name in SEC filings: Replimune Group, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
RP2	/data readout	Stage not stated	end of 2026	10-Q · Aug 14, 2026
TUDRIQEV (RP1)	Topline/data readout	Stage not stated	2026	10-Q · Aug 14, 2026

Source: ORION, orionbiotechai.com/company/REPL, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/REPL

Nearest upcoming stated timing: RP2 · Topline/data readout · end of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

RP2

Matched

Topline/data readoutend of 2026

Stage: Not stated

Public float: $234,500,000 · as of Sep 30, 2025 · SEC filing

The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.

10-Q · Filed Aug 14, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001628280-26-057099

Alert me · Calendar: same stage and window-end month (2026-12)

TUDRIQEV (RP1)

Matched

Topline/data readout2026

Stage: Not stated

Public float: $234,500,000 · as of Sep 30, 2025 · SEC filing

We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.

10-Q · Filed Aug 14, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001628280-26-057099

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
RP2Clinical results	end of 2026 “The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” Filed Aug 14, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
TUDRIQEV (RP1)Clinical results	2026 “We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.” Filed Aug 14, 2026 · 10-Q	Still within period As of Oct 19, 2026
RP2Clinical results	end of 2026 “The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” Filed Jun 29, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
TUDRIQEV (RP1)Clinical results	2026 “We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.” Filed Jun 29, 2026 · 10-K	Still within period As of Oct 19, 2026
RP2Clinical results	end of 2026 “The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” Filed Feb 3, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
TUDRIQEV (RP1)Clinical results	2026 “We are planning a publication of the ARTACUS data in 2026.” Filed Feb 3, 2026 · 10-Q	Still within period As of Oct 19, 2026
RP2Clinical results	end of 2026 “The protocol is currently being amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” Filed Nov 6, 2025 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
TUDRIQEV (RP1)Clinical results	2026 “We continue to enroll patients into the ARTACUS trial and are planning a publication of the ARTACUS data in 2026.” Filed Nov 6, 2025 · 10-Q	Still within period As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch REPL

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for REPL. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See REPL in the calendar · Review labels and methodology